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Introduction
Pre-eclampsia (PE) and fetal growth restriction (FGR) are common conditions associated with significant maternal and perinatal morbidity and mortality (1, 2) . Much of the morbidity is attributable to high rates of obstetric intervention and iatrogenic preterm delivery, indicated because of the risk of severe maternal complications and stillbirth (3) . It is recognised that PE and FGR are poorly defined manifestations of placental dysfunction, where current diagnostic criteria rely on imprecise clinical signs and/or arbitrary laboratory test cut-offs. PE is classically defined as new onset hypertension (systolic ≥140 or diastolic ≥90mmHg) occurring after 20 weeks' gestation with new proteinuria (protein:creatinine ratio ≥30mg/mmol) (4) . However, there are many atypical presentations of PE, which do not fit these diagnostic thresholds (5) . For example, women with preexisting renal disease and hypertension frequently have pre-pregnancy proteinuria, but are also at increased risk of developing PE (6) . As a result, the diagnosis of PE in this group of high-risk women is challenging and potentially contributes to the misclassification of pregnancies at highest risk of severe complications and unnecessary premature deliveries.
Recently an imbalance between pro-(placental growth factor (PlGF)) and anti-angiogenic (soluble fms-like tyrosine kinase-1 (sFlt)) factors has been implicated in the pathogenesis of PE. Preclinical (7) , in vitro (8) and ex vivo studies (9) have all demonstrated a reduction in PlGF and/or an elevation of sFlt in the context of PE and placental dysfunction. Previous clinical studies have also demonstrated that there is a significant change in circulating angiogenic markers in women who develop PE and those with related placental dysfunction (10) (11) (12) (13) . The NICE Diagnostics Assessment Panel(14) recently reviewed the published literature related to the clinical utility of angiogenic marker testing in suspected PE and concluded that a negative test could be used to safely rule out disease for the next 7-14 days (REF) . However, uncertainty about the interpretation of a positive test meant that NICE did not recommend its use to rule in disease. In view of this evidence gap we performed a clinical evaluation of PlGF testing in high-risk pregnant women with suspected PE and/or FGR, i.e. women with developing placental dysfunction. The primary aim of the study was to describe the outcome of pregnancies managed in the context of a low (<12pg/ml) or intermediate (13- 100pg/ml) PlGF measurement. The secondary outcomes were to evaluate the impact on clinical practice in a tertiary UK maternity unit and to determine whether a gestation-corrected PlGF centile would provide improved diagnostic accuracy in women with an intermediate PlGF result. After 24 weeks, all routine growth scans included fetal biometry, amniotic fluid index (AFI) and umbilical artery Doppler (UAD). In the absence of an indication to repeat the scan earlier (e.g. estimated fetal weight <10 th centile, reduction in growth velocity, AFI <5 th centile, UAD >95 th centile or absent end-diastolic-flow) ultrasound scans were repeated at 2-4 week intervals dependent on the gestation, severity of maternal disease or other clinical concerns (e.g. maternal anxiety or presentation with reduced fetal movements). In women where an abnormality was identified, additional fetal Dopplers were performed in line with standard SGA guidelines (16).
Methods

PlGF
Clinical data were entered real time using a standard electronic patient record (Viewpoint) with information related to ongoing management, clinical diagnosis and delivery planning collected centile; 26-37 weeks' gestation; 333-2190g). One of these deaths was anticipated in view of the severity of FGR (birthweight 333g) and preterm gestation (26 weeks). The two remaining deaths were not anticipated. One occurred in a pregnancy complicated by SGA identified at 26 weeks' (normal umbilical artery Doppler and continued growth) and monitored until 33+6 weeks' gestation; delivery had been arranged for 34 weeks. The third death occurred unexpectedly at 36+4 weeks in a pregnancy in which SGA had been identified at 33+6 weeks' gestation (normal liquor volume, umbilical and uterine artery Dopplers) and is discussed below.
Outcomes of pregnancies according to PlGF result
As expected, a significantly higher proportion of women (38/61; 62%) with low (<12pg/ml) PlGF delivered before 34 weeks' gestation, compared with those with a normal PlGF (9/124; 7.3%; p<0.0001). All of the women with a low PlGF had an abnormal pregnancy outcome (preterm birth and/or clinical diagnosis of PE or SGA at birth); in the group with an intermediate PlGF, 67/85 (89.3%) had an abnormal pregnancy outcome with 11 (14.7%) requiring delivery before 34 weeks. Figure 1 summarises the test-birth interval according to the PlGF result nearest delivery. In contrast to previous reports, 29/61 (48%) of women with a low PlGF continued their pregnancy for more than 14 days after the test was performed, using our care pathways. In the majority of these cases (22/29, 75.9%) this was because the pregnancy was of a gestation where conservative management was considered to be beneficial. 18/29 (62.1%) of these women had PE and 9/29 (31.0%) had SGA without features of maternal disease. Figure 1 also demonstrates "false negative" results. Test-birth interval, depending on PlGF indication and pregnancy outcome, is shown in supplementary table 1.
False negative results
In eleven pregnancies the PlGF was >100pg/ml but preterm delivery within 14 days of testing was still offered (supplementary table 2 Figure 1 ). In the majority of these cases early delivery was not indicated by placental dysfunction: spontaneous (n=1), indicated by other maternal disease (n=3) or previous history of stillbirth (n=2). In the remaining five pregnancies a decision for early delivery was 
Application of alternative cut-offs for PlGF measurement
The clinical utility of an intermediate PlGF result is uncertain (5) and in the current cohort was a poor discriminator for placental dysfunction (specificity 52.9% within 14 days of testing (n=93)). A posthoc exploratory analysis was therefore carried out by categorising PlGF using a gestation adjusted centile with a <5 th or <3 rd centile cut-off or a lower threshold of 50pg/ml to define an abnormal test using the outcomes preterm delivery (<37 weeks) and complicated pregnancy (delivery <37 weeks or >37 weeks with SGA +/-PE). Whilst there was a significant increase in the specificity of the centile cut-off, this was at the expense of the sensitivity (table 2) . In this cohort, where the test was revealed to the clinician, the test performance was comparable using the different thresholds, with slight improvement using a <3 rd centile cut-off.
The relationship between different PlGF categorisation methods and gestation at delivery were compared using cox regression. The standard cut-off at 100pg/ml (HR 1.67 [1.18-2.37]; p=0.004) was associated with an equivalent hazard ratio to a 3 rd centile cut-off (HR 2.33 [1.07-5.04]; p=0.033) but higher than a 5 th centile cut-off (HR 1.14 [0.53-2.48]; p=0.734). In women with a PlGF measurement before 34 weeks (n=157), 49/75 (65%) with a result <5 th centile delivered before 34 weeks (compared to 49/72 (68%) with a PlGF<100pg/ml); the NPV was comparable at 89%. In women with a PlGF<50pg/ml (n=62), 48 (77%) delivered <34 weeks; the comparative NPV was 85/95 (89%). Over the whole cohort 109/114 (95.6%) of women with a PlGF <5 th centile had complicated clinical outcomes, compared to 126/136 (92.6%) with a PlGF <100pg/ml and 105/109 (96.3%) using a cut-off of 50pg/ml.
Discussion
Main findings:
This study describes the clinical evaluation of a new diagnostic test for suspected PE and FGR which has recently been recommended by NICE(14) but has not been widely adopted in the UK to date. In line with previous reports we observed that a low PlGF result (<12 pg/ml) was universally associated with an adverse pregnancy outcome. However, in contrast to previous reports, in nearly half of the women in this cohort who had a low PlGF (n=61) the pregnancy continued for more than 14 days.
This most likely reflects the fact that this study included a cohort enriched with a disproportionately high number of women with severe early-onset placental dysfunction in comparison to previous studies (11, 12) , at a gestation where expectant management was desirable.
An assessment of the impact on clinical practice was captured prospectively in this study, although this is not a substitute for a randomized study, it does reflect the impact the result had on management within a tertiary centre. It is likely that maternal admissions were reduced and a significant number of ultrasound scans were safely avoided as a result of the use of a PlGF test.
However, it is important to note that scan surveillance was not reduced in all women with a normal PlGF result, demonstrating that other factors (e.g. maternal condition, obstetrician preference) will continue to influence the number of scans offered to women; this observation needs to be considered in health economic assessments in the future. Whereas the decision to offer birth was delayed in 24 pregnancies to more than 37 weeks following a normal PlGF test, we estimated that up to 42 iatrogenic preterm births were influenced by the PlGF test result. Whilst it is plausible to hypothesise that this intervention prevented some severe adverse outcomes, it highlights the potential significant increase in neonatal morbidity, which may be associated with the introduction of angiogenic marker testing in routine clinical practice. In this study we set out to estimate the impact of the perceived increase in diagnostic certainty provided by the PlGF test on obstetric decision making, but in the absence of evidence to support the prognostic value of the test or its use to 'rule-in' disease(14), local guidelines for iatrogenic birth did not include the PlGF result. There was one stillbirth (33+6 weeks) in a pregnancy complicated by a very low PlGF (n=61). Despite intensive surveillance a recognised indication for birth was not identified before the planned birth at 34 weeks.
The prevalence of pre-gestational medical disease (hypertension, renal disease, diabetes) in this cohort was much higher than the general obstetric population. This provided an important opportunity to evaluate the test in a high-risk cohort, where the diagnosis of PE by current criteria is often difficult. This study has demonstrated that PlGF was particularly useful in this group and directed a more efficient use of resources (intensive antenatal surveillance, hospital admissions and iatrogenic early delivery) without compromising maternal-fetal safety. The lack of an accepted gold standard definition of PE in women with pre-existing hypertension and renal disease, may in the future be supplanted by the incorporation of maternal serum PlGF to discriminate between deteriorating medical disease and PE.
Centile cut-offs did not offer much improvement over the traditional intermediate cut-off of 100pg/ml: specificity was improved whilst sensitivity was significantly reduced. This conclusion is consistent with prior conclusions of Chappell et al (5) .
Strength and limitations
Our study was neither randomised nor blinded to the managing clinicians, and thus our findings are potentially subject to treatment paradox. We attempted to control for this by conducting the study in a specialist unit, deploying resources to maximise gestational age at delivery. Despite these limitations we feel the study has important implications for adoption of this test in high-risk women with suspected placental dysfunction. Despite the absence of a comparison group, this prospective clinical evaluation study was designed with contemporaneous data collection and therefore aimed to capture and describe the impact of the test on clinician practice in the management of suspected placental dysfunction. Furthermore, in this study it was only possible to compare PlGF measurements to clinical diagnoses, which are frequently incorrect. A much more robust comparison would include placental histological assessment, thereby increasing the certainty of underlying placental dysfunction. An additional limitation is that this study was carried out in a tertiary referral centre within a high-risk cohort and a disproportionately high rate of preterm placental disease, which may limit applicability to general obstetric populations. A step-wedge randomised study (PARROT ISRCTN16842031) is currently underway at several hospitals in the UK (including St Mary's, Manchester) and will evaluate the time to diagnosis of PE before and after implementation of PlGF testing in women presenting with suspected PE. The PARROT study will also provide important supplementary cost utility information that can be added to the NICE Diagnostic Assessment Panel (14) cost evaluation; this was not possible in the current study due to the lack of a comparator group. Finally, we assume that the link between iatrogenic preterm birth and low maternal PlGF is underlying placental dysfunction resulting in an abnormal angiogenic secretory pattern from placental villi (20, 21) . Future studies in high-risk women would benefit from the inclusion of placental pathology (22) .
Interpretation
The selective use of PlGF testing influenced the clinical management of women with suspected placental dysfunction potentially both reducing and increasing intervention where required.
Although inevitably decisions on intervention were influenced by the PlGF result, women were not delivered on a PlGF result alone. This is demonstrated by the high number of pregnancies that continued >14 days when PlGF was <12pg/ml without adverse outcome and highlights the need for the PlGF result to be taken in context with other validated prognostic markers such as umbilical artery Doppler measurement.
In the UK, the NICE diagnostic assessment panel(14) recently recommended angiogenic marker testing to exclude PE within one week. This was based on data from studies using PlGF and the sFlt:PlGF ratio (5, 11) . Our results support this recommendation for placental dysfunction with a maternal component, as we had no diagnoses of PE within 7 days of a normal PlGF result. In this high-risk cohort angiogenic marker testing also assisted in the management of suspected SGA with a detection rate of 80% within a week, however two cases of severe FGR were not identified by an abnormal PlGF result (test-birth interval 5 days) highlighting the heterogeneous aetiology of this condition and the ongoing need for further research regarding the relationship between placental dysfunction and maternal angiogenic marker levels (13) .
To conclude, our evaluation confirms the value of PlGF as a highly valuable diagnostic tool for placental dysfunction, particularly in the presence of maternal disease, which is likely to influence obstetric management and timing of birth. However, it has highlighted that several evidence gaps remain which should caution the introduction of this test into routine clinical practice, particularly in normotensive SGA. It also confirms that abnormal PlGF levels in isolation are not an indication for delivery. Further research linking placental pathology, maternal disease and maternal PlGF levels is therefore urgently needed to further inform the clinical utility of angiogenic marker tests.
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